FeTMPyP
Based on 1 publication(s) in Google Scholar
FeTMPyP is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. FeTMPyP inhibits cell death, nitrotyrosine formation, and depolarization of mitochondrial transmembrane potential. FeTMPyP reduces homocysteine-induced nitrosative stress and partially restores TFEB protein and mRNA levels. FeTMPyP improves functional and behavioral deficits caused by chronic constriction injury in rats. FeTMPyP alleviates acute cerebral infarction in a rat model of middle cerebral artery occlusion with mild hyperglycemia. FeTMPyP can be used in studies related to neuropathic pain, renal aging, ischemic penumbra, and hyperglycemic stroke.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.98%
- No. CAS: 133314-07-5
- Fòrmula: C44H36Cl5FeN8
- Peso molecular:909.92
-
Almacenamiento:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Anti-Aging Compound Library
HY-L034
-
Orally Active Compound Library
HY-L061
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) FeTMPyP
More
Actividad biológica
FeTMPyP partially rescues the reduction in TFEB protein expression caused by Hcy stimulation in MPC-5 mouse podocyte cells[2].
FeTMPyP (0.01-100 μM; 6 h) concentration-dependently reduces LDH release, a marker of cell death, in glucose-deprived immunostimulated rat prefrontal cortex astrocytes after 6 h of treatment[3].
FeTMPyP (0.01-100 μM; 4 h) reduces LDH release in SIN-1-treated, glucose-deprived rat prefrontal cortex astrocytes after 4 h of treatment[3].
FeTMPyP (10 μM; 6 h) inhibits the increase in nitrotyrosine immunoreactivity, a marker of peroxynitrite, in glucose-deprived immunostimulated rat prefrontal cortex astrocytes[3].
FeTMPyP (10 μM; 3 h) inhibits the increase in nitrotyrosine immunoreactivity, a marker of peroxynitrite, in SIN-1-treated, glucose-deprived rat prefrontal cortex astrocytes[3].
FeTMPyP (0.33-50 μM; 15 min) concentration-dependently inhibits peroxynitrite-mediated tyrosine nitration of bovine serum albumin in a cell-free assay after 15 min of incubation[3].
FeTMPyP (10 μM) inhibits peroxynitrite-mediated oxidation of DCF-H to DCF in SIN-1-treated, glucose-deprived rat prefrontal cortex astrocytes[3].
FeTMPyP (10 μM; 3 h) prevents mitochondrial transmembrane potential depolarization in SIN-1-treated, glucose-deprived rat prefrontal cortex astrocytes over 3 h of co-treatment[3].
FeTMPyP (50 μM; full experimental protocol) reverses HG MCAO plasma-induced increases in myogenic tone and lumen narrowing in isolated nonischemic rat MCA, likely via inhibiting the vasoconstricting properties of peroxynitrite[4].
FeTMPyP (50 μM; full experimental protocol) does not alter HG Sham plasma-induced increases in myogenic tone in isolated nonischemic rat MCA, indicating peroxynitrite is not involved in this response[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:rat prefrontal cortex astrocytes
-
Concentration:0.01-100 μM
-
Incubation Time:6 h
-
Result:Attenuated astrocyte death in a concentration-dependent manner, and reduced LDH release in glucose-deprived immunostimulated astrocytes.
-
Cell Line:rat prefrontal cortex astrocytes
-
Concentration:0.01-100 μM
-
Incubation Time:4 h
-
Result:Blocked the augmented astrocyte death induced by glucose deprivation plus SIN-1 treatment.
-
Cell Line:rat prefrontal cortex astrocytes
-
Concentration:10 μM
-
Incubation Time:6 h
-
Result:Completely blocked the elevated nitrotyrosine immunoreactivity observed in glucose-deprived immunostimulated astrocytes.
-
Cell Line:rat prefrontal cortex astrocytes
-
Concentration:10 μM
-
Incubation Time:3 h
-
Result:Completely blocked the elevated nitrotyrosine immunoreactivity observed in SIN-1-treated, glucose-deprived astrocytes.
FeTMPyP (10 mg/kg; i.v.; single dose 10 minutes before reperfusion) acutely reduces corrected acute infarct volume by ~72% in hyperglycemic rats with mild ischemic stroke (<68% CBF decrease) but provides no neuroprotection in rats with severe ischemic stroke (>68% CBF decrease), with no effect on reperfusion CBF[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (male, 180-230 g, chronic constriction injury of left sciatic nerve)[1]
-
Dosage:1 mg/kg; 3 mg/kg
-
Administration:p.o.; daily; 14 days
-
Result:Significantly improved sciatic functional index (SFI) at 3 mg/kg.
Increased paw withdrawal latencies to cold (4°C) and hot (52.5°C) thermal stimuli, increased paw withdrawal thresholds to mechanical von Frey filament stimuli , and reduced cold chemical allodynia scores from acetone spray tests relative to CCI controls on day 14 at 3 mg/kg.
Reversed CCI-induced foot deformity at both 1 mg/kg and 3 mg/kg.
Significantly reduced sciatic nerve malondialdehyde (MDA) levels and nitrite levels.
Reversed CCI-induced elevations in iNOS, COX-2, and phospho-NF-κB protein expression and restored reduced Nrf2 and HO-1 protein expression.
-
Animal Model:Wistar rats (male, ≈300 g, hyperglycemic model via streptozotocin injection, transient middle cerebral artery occlusion reperfusion)[4]
-
Dosage:10 mg/kg
-
Administration:i.v.; single dose 10 minutes before reperfusion
-
Result:Reduced corrected acute infarct volume in rats with mild ischemia.
Showed no significant effect on corrected acute infarct volume in rats with severe ischemia.
Did not alter reperfusion CBF in either mild or severe ischemia groups.
Chemical Information
-
No. CAS 133314-07-5
-
Appearance Solid
-
Peso molecular 909.92
-
Fòrmula C44H36Cl5FeN8
-
Color Brown to black
-
SMILES
C[N+](C=C1)=CC=C1C2=C3C=CC(C(C4=CC=[N+](C)C=C4)=C5C=CC([N-]56)=C7C8=CC=[N+](C)C=C8)=[N]3[Fe+3]96[N]%10=C7C=CC%10=C(C%11=CC=[N+](C)C=C%11)C%12=CC=C2[N-]%129.[5Cl-]
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvente y solubilidad
H2O : 3.57 mg/mL (3.92 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (286 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Komirishetty P, et al. FeTMPyP a peroxynitrite decomposition catalyst ameliorated functional and behavioral deficits in chronic constriction injury induced neuropathic pain in rats. Free Radic Res. 2021;55(9-10):1005-1017. [Content Brief]
[2]. Zhang S, et al. Nitrative Stress-Related Autophagic Insufficiency Participates in Hyperhomocysteinemia-Induced Renal Aging. Oxid Med Cell Longev. 2020;2020:4252047. Published 2020 Jan 25. [Content Brief]
[3]. Choi IY, et al. Augmented death in immunostimulated astrocytes deprived of glucose: inhibition by an iron porphyrin FeTMPyP. J Neuroimmunol. 2001;112(1-2):55-62. [Content Brief]
[4]. Palomares SM, et al. Peroxynitrite decomposition with FeTMPyP improves plasma-induced vascular dysfunction and infarction during mild but not severe hyperglycemic stroke. J Cereb Blood Flow Metab. 2012;32(6):1035-1045. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.0990 mL | 5.4950 mL | 10.9900 mL | 27.4749 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
FeTMPyP Related Classifications
HY-120380 Related Classifications
Powered by Bioz